UK markets closed

Lyra Therapeutics, Inc. (LYRA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.2702+0.0086 (+3.29%)
At close: 04:00PM EDT
0.2700 -0.00 (-0.07%)
After hours: 07:27PM EDT

Lyra Therapeutics, Inc.

480 Arsenal Way
Watertown, MA 02472
United States
617 393 4600
https://lyratherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees109

Description

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Corporate governance

Lyra Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.